iTeos Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-22. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tang Capital Management, LLC | 100% | 10,000 | SCHEDULE 13D/A, 2025-09-03 | 2025-08-29 |
| Ridgeback Capital Investments L.P. | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Purpose of Transaction (Item 4)
Tang Capital Management, LLC
Item 4 of the Schedule 13D is amended by adding the following: Closing of the Merger: As previously disclosed, each of Concentra, the Issuer and Merger Sub entered into the Merger Agreement, which provides for an Offer by Merger Sub for all of the Issuer's Common Stock. The Offer commenced on August 1, 2025. On August 29, 2025, the Offer expired and Merger Sub accepted for purchase a total of 32,226,407 shares tendered and not withdrawn, representing approximately 72.17% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on August 29, 2025, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into the right to receive the Offer Price, with the Issuer surviving as a wholly owned subsidiary of Concentra.Item 4 of the SCHEDULE 13D/A filed 2025-09-03
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-22 | Tang Capital Management, LLC | 9.99% | SCHEDULE 13D/A |
| 2025-07-25 | Ridgeback Capital Investments L.P. | 5.1% | SCHEDULE 13G |
| 2025-08-14 | Biotechnology Value Fund L P | 0% | SCHEDULE 13G/A |
| 2025-09-03 | Tang Capital Management, LLC | 100% | SCHEDULE 13D/A |
| 2025-11-14 | Ridgeback Capital Investments L.P. | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for iTeos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.